Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Mar;25(3):754.
doi: 10.1093/annonc/mdt595. Epub 2014 Feb 4.

Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer--a problem still to be solved

M Schmidt  1 , M Untch  2
Affiliations
Comment

Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer--a problem still to be solved

M Schmidt et al. Ann Oncol. 2014 Mar.

Abstract

We read with great interest the manuscript of the 13th St Gallen International Breast Cancer Conference (Goldhirsch et al. Ann. Oncol. 2013, 24, 2206-2223). Concerning multi-gene signatures the” 21-gene RS is accepted as providing not only prognostic, but also predictive information regarding the utility of cytotoxic therapy in addition to endocrine therapy for patients with luminal disease.

This is a definite statement, however, we want to draw attention to the fact that this evidence is based on two clinical trials including also HER2-positive breast cancer patients. This inclusion of HER2-positive patients might alter the predictive value of RS in luminal HER2-negative breast cancer patients and we thus consider it important to discuss this issue publicly.

PubMed Disclaimer

Comment in

Comment on

References

    1. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–2223. - PMC - PubMed
    1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734. - PubMed
    1. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444. - PMC - PubMed
    1. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65. - PMC - PubMed